Search the Newsreel

No deal between AstraZeneca and BMS, senior source insists: Reuters

Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approximately …

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol Myers Squibb's stock …

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on potential talks …

Dimensional Fund Advisors LP Raises Stake in Myers Industries, Inc. $MYE

Dimensional Fund Advisors LP increased its stake in Myers Industries, Inc. ($MYE) by 2.6% in the first quarter, now holding 1.59 million shares valued at approximately $33.7 million. Institutional investors collectively own 90.82% of the company. Myers Industries recently reported strong quarterly earnings, beating …

Myers Industries (NYSE:MYE) Hits New 12-Month High - Still a Buy?

Myers Industries (NYSE:MYE) recently hit a new 52-week high of $37.45, fueled by strong Q2 earnings that surpassed analyst estimates and an upgraded price target from KeyCorp. The company reported EPS of $0.53 and revenue of $179.2 million, significantly beating expectations. Despite a consensus …

‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters

Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. The Financial Times report had caused AstraZeneca's stock to drop, while the Reuters news led to a rebound for AZ …

Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb's stock fell 1.4% in premarket trading following a report that there are no ongoing discussions with AstraZeneca regarding a potential deal. Conversely, AstraZeneca's shares rose by 5.6% after the news. The report explicitly stated that no deal ever existed between the two …

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Argus has upgraded Bristol-Myers Squibb (BMY) to a "Buy" rating from "Hold," setting a new price target of $75. The company currently holds an average rating of "overweight" with a mean price target of $66 among analysts. The full MT Newswires article with further …

Bristol-Myers Squibb Co (BMY) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

AstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExec

AstraZeneca and Bristol Myers Squibb recently held discussions about a potential merger that would create the world's largest pharmaceutical company by revenue, with a combined market capitalization of nearly $400 billion. The report, though unconfirmed by either company, led to a drop in AstraZeneca …

Why Myers Industries (MYE) Is Up 8.7% After Strong Q2 Profitability And Expanded Credit Facilities – And What's Next

Myers Industries (MYE) saw an 8.7% stock increase following strong Q2 2026 sales and net income, along with an expanded credit facility that includes a new $250 million term loan and extended revolving credit. This financial restructuring aims to enhance flexibility as the company …

Myers Industries (MYE) Following Strong Q2 Results, Is The Valuation Case Still Intact?

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Analysts are describing a potential merger between AstraZeneca and Bristol Myers Squibb as "odd," despite its potential to create a major cancer-drug powerhouse. The Financial Times reported early-stage talks, leading to AstraZeneca shares closing lower and Bristol Myers Squibb remaining flat. This merger would …

Bristol Myers Squibb, AstraZeneca reportedly weigh $400B merger

U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. If successful, this tie-up would create the world’s fourth-largest drugmaker by market value and the largest by revenue, uniting their strengths in oncology, immunology, …

Myers Industries Inc Today's Market Trends | MYE Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

Myers Industries Inc (MYE) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Containers & Packaging industry. The stock has seen significant price increases over the past year, and analysts have a "Buy" rating with a target …

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

BioNTech Aktie: BNT327 mit Bristol Myers Squibb

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Jim Cramer expressed skepticism regarding the rumored $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, calling it a potential "fake out" and suggesting BMY needs assistance. The Financial Times reported ongoing discussions, which could lead to a cash and stock deal, combining AstraZeneca's …

Gabelli group holds 5,054,709 Myers Industries (NYSE: MYE) shares

Entities affiliated with Mario Gabelli beneficially own 5,054,709 shares of Myers Industries (NYSE: MYE) common stock, representing 13.44% of the outstanding shares as of June 30, 2026. This ownership is detailed in a Schedule 13D/A filing, noting key holders include GAMCO Asset Management and …

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

The article argues that a potential merger between AstraZeneca and Bristol Myers Squibb, valued at nearly $400 billion, would be a disaster. It highlights severe regulatory concerns due to significant portfolio overlaps, potential pipeline disruptions, and massive job losses as key reasons against such …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

Bristol-Myers Squibb Company supera las previsiones de los analistas: descubre cuáles son las previsiones de consenso para este año

Lazard Asset Management LLC Purchases 64,018 Shares of Myers Industries, Inc. $MYE

Lazard Asset Management LLC significantly increased its stake in Myers Industries, Inc. (NYSE:MYE) during the first quarter, purchasing an additional 64,018 shares to hold a total of 155,766 shares valued at approximately $3.3 million. This comes as Myers Industries reported strong second-quarter results, exceeding …

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

KeyBanc Maintains Myers Industries(MYE.US) With Buy Rating, Maintains Target Price $37

KeyBanc has reaffirmed its Buy rating for Myers Industries (MYE.US) and maintained its target price of $37. This indicates a continued positive outlook from the firm regarding the company's stock performance.